Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,980 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, Tanaka M, Kako S, Matsuda M, Yokoyama H, Ishikawa Y, Taniguchi Y, Hagihara M, Ozawa Y, Ueda Y, Hirano D, Sakura T, Tsuji M, Kamae T, Fujita H, Hiramoto N, Onoda M, Fujisawa S, Hatta Y, Dobashi N, Nishiwaki S, Atsuta Y, Kobayashi Y, Hayakawa F, Ohtake S, Naoe T, Miyazaki Y. Sugiura I, et al. Among authors: tsuji m. Blood Adv. 2022 Jan 25;6(2):624-636. doi: 10.1182/bloodadvances.2021004607. Blood Adv. 2022. PMID: 34516628 Free PMC article. Clinical Trial.
Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT.
Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, Kanda J, Ishikawa T, Imada K, Ueda Y, Toda Y, Anzai N, Yago K, Nohgawa M, Yonezawa A, Tsunemine H, Itoh M, Yamamoto K, Tsuji M, Moriguchi T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Matsui H, et al. Among authors: tsuji m. Blood Adv. 2020 Jul 14;4(13):3169-3179. doi: 10.1182/bloodadvances.2020002007. Blood Adv. 2020. PMID: 32658984 Free PMC article.
Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
Muranushi H, Kanda J, Kobayashi M, Maeda T, Kitano T, Tsuji M, Ueda Y, Ishikawa T, Nohgawa M, Watanabe M, Imada K, Moriguchi T, Itoh M, Ohno H, Yonezawa A, Hirata H, Arima N, Asagoe K, Anzai N, Nagata K, Yasuno S, Kuwabara Y, Kitao H, Kim I, Kawagishi K, Ueshima K, Tominari S, Nakayama T, Yamashita K, Takaori-Kondo A. Muranushi H, et al. Among authors: tsuji m. Hematology. 2022 Dec;27(1):239-248. doi: 10.1080/16078454.2022.2032915. Hematology. 2022. PMID: 35152852 Free article. Clinical Trial.
Coexistence of HLA and KIR ligand mismatches as a risk factor for viral infection early after cord blood transplantation.
Iemura T, Arai Y, Kitawaki T, Kanda J, Kondo T, Ueda Y, Mori T, Imada K, Yonezawa A, Yago K, Anzai N, Kotani S, Nohgawa M, Kitano T, Itoh M, Arima N, Moriguchi T, Watanabe M, Tsuji M, Yamashita K, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Iemura T, et al. Among authors: tsuji m. Bone Marrow Transplant. 2022 May;57(5):781-789. doi: 10.1038/s41409-022-01621-w. Epub 2022 Mar 2. Bone Marrow Transplant. 2022. PMID: 35236933
Epitope Mismatch at HLA-DRB1 Associates with Reduced Relapse Risk in Cord Blood Transplantation for Standard-Risk Hematologic Malignancy.
Morita-Fujita M, Shindo T, Iemura T, Arai Y, Kanda J, Okada K, Ueda Y, Yoshiyuki O, Anzai N, Mori T, Ishikawa T, Otsuka Y, Yonezawa A, Yuhi N, Imada K, Oba A, Itoh M, Okamoto Y, Kitano T, Ikeda T, Kotani S, Akasaka T, Yago K, Watanabe M, Nohgawa M, Tsuji M, Takeoka T, Yamamoto R, Arima N, Yoshinaga N, Hishizawa M, Yamashita K, Kondo T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group. Morita-Fujita M, et al. Among authors: tsuji m. Transplant Cell Ther. 2023 Jun;29(6):347.e1-347.e11. doi: 10.1016/j.jtct.2023.03.002. Epub 2023 Mar 6. Transplant Cell Ther. 2023. PMID: 36889508
1,980 results